Washington Post Company (WPO) - FREE Research Report

Weymouth Katharine who is Director at Washington Post Company sold 3,992 shares at $610.65 on Oct. 11, 2013. Following this transaction, the Director owned 19,721 shares meaning that the stake was reduced by 16.83% with the 3,992 share transaction.

The shares most recently traded at $610.35, down $0.30, or 0.05% since the insider transaction. Historical insider transactions for Washington Post Company go as follows:

  • 4-Week # shares sold: 7,333
  • 12-Week # shares sold: 7,333
  • 24-Week # shares sold: 7,333

The average volume for Washington Post Company has been 33,000 shares per day over the past 30 days. Washington Post Company has a market cap of $3.7 billion and is part of the services sector and media industry. Shares are up 61.7% year to date as of the close of trading on Friday.

The Washington Post Company, together with its subsidiaries, operates as a diversified education and media company in the United States and internationally. The stock currently has a dividend yield of 1.66%. The company has a P/E ratio of 91.6. Currently there are no analysts that rate Washington Post Company a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on WPO - FREE

TheStreet Quant Ratings rates Washington Post Company as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, good cash flow from operations, expanding profit margins and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Washington Post Company Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

These Stocks Are Ready to Reverse Course

Don't Get Out of Joint

Zimmer Biomet: Cramer's Top Takeaways

Market Stands at a Make-Or-Break Level: Cramer's 'Mad Money' Recap (Monday 7/17/17)

Analyst Says Rival Bidder Could Emerge for Novadaq After Stryker Deal